Header Logo

Connection

Co-Authors

Back to Details
This is a "connection" page, showing publications co-authored by JOSEPH A LUDWIG and JOHN ANDREW LIVINGSTON.
JOSEPH A LUDWIG
Connection Strength
0.597
JOHN ANDREW LIVINGSTON
  1. Transcriptional activators YAP/TAZ and AXL orchestrate dedifferentiation, cell fate, and metastasis in human osteosarcoma. Cancer Gene Ther. 2021 12; 28(12):1325-1338.
    View in: PubMed
    Score: 0.191
  2. IGF-1R/mTOR Targeted Therapy for Ewing Sarcoma: A Meta-Analysis of Five IGF-1R-Related Trials Matched to Proteomic and Radiologic Predictive Biomarkers. Cancers (Basel). 2020 Jul 02; 12(7).
    View in: PubMed
    Score: 0.184
  3. Does the Primary Tumor Site Drive Biology for Patients With Synovial Sarcoma? Am J Clin Oncol. 2024 Sep 03.
    View in: PubMed
    Score: 0.061
  4. Outcomes of Late-Line Systemic Treatment in GIST: Does Sequence Matter? Cancers (Basel). 2024 Feb 23; 16(5).
    View in: PubMed
    Score: 0.059
  5. Retrospective evaluation of the role of gemcitabine-docetaxel in well-differentiated and dedifferentiated liposarcoma. Cancer Med. 2023 02; 12(4):4282-4293.
    View in: PubMed
    Score: 0.054
  6. Outcomes of systemic therapy in metastatic phyllodes tumor of the breast. Breast Cancer Res Treat. 2021 Apr; 186(3):871-882.
    View in: PubMed
    Score: 0.048
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.